Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 5:08 AM
Ignite Modification Date: 2025-12-26 @ 4:12 AM
NCT ID: NCT00713427
Description: Reported on Adverse Events (Serious and Non-serious) related to the device and/or procedure.
Frequency Threshold: 0
Time Frame: Adverse event data collected from the time the participant signed the informed consent until completion of the 6 month follow-up visit (occurring 6 months post-initial study treatment)
Study: NCT00713427
Study Brief: Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
WallFlex Stent All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted. WallFlex™ Biliary Partially-Covered Stent: Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent. 0 None 9 69 0 69 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Recurrent Biliary Obstruction SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (15.0) View
Cholecystitis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (15.0) View
Pancreatitis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (15.0) View
Right Upper Quadrant Pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (15.0) View
Other Events(If Any):